Lab Discovery Revolutionizes Cancer Treatments

Scientist examining samples under a microscope in a laboratory

Scientists have found a way to “step on the gas” of your immune system’s natural killer cells without permanently rewiring them—and if it holds up in humans, it could quietly rewrite how we treat some of the nastiest cancers on earth.

Story Snapshot

McGill researchers boosted natural killer cells by blocking two brake-like proteins, turning them into far more lethal cancer hunters in lab and animal tests.
The method uses reversible drugs, not permanent gene editing, aligning with a safer, more controllable, and potentially cheaper model of immunotherapy.
The strategy hit multiple aggressive cancers, from leukemia to triple-negative breast cancer, in preclinical work.
The entire promise still hangs on a familiar question: will impressive mouse and petri-dish victories survive the brutal reality of human trials?

Natural killer cells: your built‑in hit squad that tumors learn to disarm

Most people think of the immune system as a vague “strong or weak” thing, but natural killer cells are more like a standing special-operations unit. They are hard-wired to recognize stressed, infected, or transformed cells and kill them on sight, without waiting for the rest of the immune bureaucracy to vote on it. In healthy people, that constant quiet culling helps keep microscopic cancers from ever becoming a doctor’s problem. The catch is that advanced tumors rarely play fair.

Solid and blood cancers both evolve tricks to blunt natural killer cells: they secrete suppressive factors, remodel the local tissue into a hostile swamp, and manipulate the signaling pathways that normally tell natural killer cells when to attack and when to stand down. Reviews of natural killer cell biology show that inside real tumors these cells are often exhausted, underfed, and chemically muzzled, far from the ruthless killers they look like in textbooks. That suppression problem is exactly what the McGill group decided to attack at the wiring level.

The McGill strategy: release the brakes, do not rebuild the engine

The McGill team focused on two specific proteins inside natural killer cells that act like internal brakes on activation signaling.^[1]^[2] When these proteins—identified in the paper as PTPN1 and PTPN2—are active, they dampen the natural killer cell response to growth and survival signals like interleukin-2 and make the cells more vulnerable to TGF-beta, a classic tumor-suppressive signal.^[1]^[2] Block those proteins, and the same natural killer cell suddenly hears the “go kill” messages louder and the “stand down” messages less.

In a series of preclinical experiments, the researchers either removed or pharmacologically inhibited PTPN1 and PTPN2, then watched what happened when they confronted these tuned-up natural killer cells with human cancer cells in culture and in animal models.^[1]^[2] The result, in their telling, was not a subtle tweak: the altered cells destroyed human leukemia, glioblastoma, kidney cancer, and triple-negative breast cancer cells, and slowed tumor growth when tested in mice.^[1]^[2] For a field obsessed with incremental gains, that breadth of effect naturally raised eyebrows.

Why reversible drugs matter to safety, cost, and common sense

Many current cell-based immunotherapies depend on genetic editing: take cells from a patient, permanently rewire them in a laboratory, expand them, and reinfuse them. That process is expensive, slow, and hard to reverse if something goes wrong. The McGill approach goes in the opposite direction. Rather than hard-coding a permanent change, they used small-molecule drugs to temporarily inhibit PTPN1 and PTPN2 in natural killer cells, boosting their activity only as long as the drugs are present.^[1]^[2]

The team and their institutional communications frame this as a potential safety and affordability win.^[1]^[2] From a conservative, risk-aware standpoint, this logic tracks: a reversible chemical “on switch” that you can dial up or down with dosing looks more aligned with common sense than permanently installing a genetic turbocharger you cannot easily remove. If adverse effects emerge, stop the drug and the system drifts back toward baseline. That kind of control is precisely what regulators and cautious clinicians usually want before they unleash anything that can kill cells that look even vaguely like “self.”

From lab bench to leukemia patients: promising path, brutal filter

The researchers are targeting acute myeloid leukemia as an early clinical focus, an aggressive blood cancer where traditional chemotherapy and transplants still leave many patients with grim odds.^[1]^[2] A separate McGill-led initiative, funded with millions through Genome Canada, aims to build an “off-the-shelf” cord-blood natural killer cell bank and protocols for national clinical trials in hard-to-treat cancers like acute myeloid leukemia.^[4]^[6] That broader program suggests serious institutional backing rather than a one-off press release.

Scientists at McGill University have found a way to supercharge the immune system’s natural killer (NK) cells, helping them break through the defenses tumors use to stay alive. By temporarily blocking two proteins, researchers turned these cells into far mhttps://t.co/HC2xfcFNMK

— Michael W. Deem (@Michael_W_Deem) May 25, 2026

Yet all the impressive cancer-killing so far exists in the preclinical world: controlled dishes and carefully bred mice.^[1]^[2]^[5] The public summaries do not show quantitative effect sizes, durability over time, or systematic toxicology. They do not offer direct head-to-head comparisons against other ways of boosting natural killer cells, such as interleukin-15 superagonists, engineered chimeric antigen receptor natural killer cells, or antibody-based checkpoint inhibitors, all of which have their own encouraging mouse data and early trials.^[5]

How this fits into the larger natural killer cell arms race

Natural killer cell therapy is not a lonely moonshot; it is one of the busiest frontiers in immuno-oncology.^[5] Researchers have shown that cytokines like interleukin-2 and interleukin-15 can expand and activate natural killer cells, that chimeric antigen receptors can redirect them toward specific targets, and that even tiny extracellular vesicles shed by natural killer cells may be weaponized as cell-free therapies.^[4]^[5] Other groups are finding different “checkpoints”—genes like CALHM2—that, when removed or blocked, improve natural killer cell infiltration and killing in solid tumors.^[3]

The McGill angle—temporary pharmacologic release of PTPN1 and PTPN2 brakes—should be viewed as one promising piece of that competition, not the final word. From a practical, taxpayer-conscious standpoint, that competition is healthy. It means funders and regulators can compare strategies on clear metrics: which approach delivers the most tumor control per dollar, with the least collateral damage, and with mechanisms simple enough that ordinary hospitals can deploy them without becoming bespoke gene-editing factories. The reversible, small-molecule model will appeal strongly if it can deliver even comparable results.